Posted by Michael Wonder on 02 Jul 2024
Valneva receives marketing authorisation in Europe for the world’s first chikungunya vaccine Ixchiq
1 July 2024 - 2024 – Valneva today announced that the European Commission has granted marketing authorisation in Europe for Valneva’s single dose vaccine, Ixchiq, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
The approval was unanimously endorsed by Member States following a stringent assessment by the EMA.
